Deep brain stimulation in Parkinson's disease patients and routine 6‐OHDA rodent models: Synergies and pitfalls. (23rd October 2020)

• Record Type: Journal Article
• Authors: Stefani, Alessandro; Cerroni, Rocco; Pierantozzi, Mariangela; D'Angelo, Vincenza; Grandi, Laura; Spanetta, Matteo; Galati, Salvatore
• Is Part Of: European journal of neuroscience. Volume 53:Number 7(2021)
• Page Start: 2322
• Page End: 2343
• Publication Date: 2020-10-23
• Subjects: 6‐OHDA -- beta band -- MPTP -- neuronal oscillations -- subthalamic nucleus; Nervous system -- Periodicals; 612.8
• DOI: 10.1111/ejn.14950
• Languages: English
• ISSNs: 0953-816X

Abstract

Abstract: The history of deep brain stimulation for Parkinson's disease (PD) represented a paradigmatic cross‐talk between mammalian disease models and clinical evidence in humans. Fascinating were the results achieved by high frequency stimulation (HFS) into the subthalamic nucleus (STN) of MPTP‐treated primates. An analogous strategy relieved tremor and hypokinetic parameters in PD patients. The 6‐hydroxydopamine (6‐OHDA) rodent model has mastered decades of research, contributing to understanding of the PD pathology. However, this review wonders about the actual synergy between the routine neurotoxic models and PD patients underlying STN‐DBS. At first, some findings collected following 6‐OHDA, promoted dogmatic visions, as the wrong contention that suppression of STN glutamate was the key therapeutic player. Instead, changes of glutamate release are negligible in humans during transition to ON‐state. Besides, the imbalance of basal ganglia endogenous band frequencies, the beta (β) band increase and the cortical‐basal ganglia synchronization, undisputedly shared by models and PD patients, do not govern the whole spectrum of non‐motor PD signs, difficult to investigate in rodents. Furthermore, the tonic release of dopamine, inferred during HFS in rodents, was not replicated in humans. Finally, neurotoxic rodent models describe a 'pure' dopamine depletion sparing pathways crucial in parkinsonian phenotypes, that is, noradrenergic and cholinergic ones. Although the utilization of neurotoxic models is still providing major advancements, we pore over these contradictions and try to support possible amendments of neurotoxic models (advocating modern 'in vivo' approaches and recordings extending towards motor thalamus) for pursing the development of new DBS technology. Abstract : A constant exchange of information, between results emerging from neurotoxic rodent models of Parkinson's disease and findings collected from PD patients submitted to neurosurgery and deep brain stimulation onto basal ganglia stations, has fuelled decades of research and brilliant achievements. Yet, this synergistic cooperation is now declining, given that DBS in humans develops new technologies hard to replicate in small mammals and, moreover, emphasizes also the role of non‐dopaminergic pathway, intrinsically neglected following 6‐OHDA. This manuscript aims at addressing this scenario and tries to delineate new research avenue in order to renovate the experimental setting.